Brainstorm Cell Therapeutics Inc at Sachs Associates Neuroscience Innovation Forum Transcript
Okay. You're on? Okay. Thank you very much. So pleasure to be here. I'm the Chief Operating Officer and Chief Medical Officer of Brainstorm Cell Therapeutics. And I'm going to give you an update on our progress. 2020 should be a very exciting year for us. We're a publicly traded company. So here's our disclosure statement. Similar to others.
What's different about Brainstorm Cell Therapeutics? Well, first of all, we have about 12 or 14 year history of developing cellular therapeutics. I think we have very strong technology platform, CMC and IP protection. We have a laser focus on neurodegenerative diseases, particularly ALS which is in Phase 3, and progressive MS, which contrary to my prior speaker, is in Phase 2. So it's a surprise to you maybe.
We have a very strong background of preclinical work across the neurodegenerative disease spectrum, including animal models of Parkinson's disease, Huntington's, and so on. The unmet medical need and the market opportunity for these diseases is huge, and I think that we
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
